Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

PCSK9 Antibodies Treatment Specifically Enhances the Macrophage-specific Reverse Cholesterol Transport Pathway in Heterozygous Familial Hypercholesterolemia

  • Borràs, Carla|||0000-0002-0998-7855
  • Canyelles, Marina|||0000-0002-0278-5337
  • Girona, Josefa
  • Ibarretxe, Daiana
  • Santos, David|||0000-0003-1157-4969
  • Revilla, Giovanna|||0000-0003-2971-5651
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Kovanen, Petri T.
  • Jauhiainen, Matti|||0000-0002-3836-3785
  • Lee-Rueckert, Miriam
  • Masana, Luis|||0000-0002-0789-4954
  • Arrieta, Francisco|||0000-0001-7571-0451
  • Martínez-Botas, Javier|||0000-0002-5190-3619
  • Gómez-Coronado, Diego|||0000-0002-8382-3920
  • Ribalta, Josep|||0000-0002-8879-4719
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
We investigated the potential of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies torestore macrophage cholesterol efflux in subjects with heterozygous familial hypercholesterolemia (FH)and to enhance the macrophage-specific reverse cholesterol transport pathway in mice. Analyses ofmacrophage-derived cholesterol distribution of plasma from FH patients revealed that low-density li-poprotein (LDL) particles contained less, and high-density lipoprotein particles contained more radio-labeled cholesterol after treatment with either PCSK9 inhibitor. PCSK9 antibodies facilitated thetransfer of macrophage-derived cholesterol and LDL-derived cholesterol to feces exclusively inheterozygous LDL receptor-deficient mice expressing human APOB100. PCSK9 inhibitors act aspositive regulators of the macrophage-specific reverse cholesterol transport pathway in individuals withheterozygous FH.